 SOUTH SAN FRANCISCO, Calif.--BUSINESS WIRE--Five Prime Therapeutics, Inc. Nasdaq: FPRX, announced today the pricing of an underwritten public offering of 7,200,000 shares of its common stock at a price to the public of 21.00 per share. The size of the offering was upsized from 5,000,000 shares to 7,200,000 shares. Five Prime estimates that the net proceeds from the sale of the shares will be approximately 141.9 million, after deducting underwriting discounts and commissions and estimated 